Oyster Point Pharmaceuticals Inc., a San Francisco, CA-based developer of novel therapies for dry eye and other diseases of the ocular surface, completed a $22m Series A financing.
The round was led by New Enterprise Associates and Versant Ventures.
The company intends to use the proceeds for Phase II clinical trials of its lead compounds.
Ked by President and CEO Jeffrey Nau, Ph.D., MMS., Oyster Point Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat ocular surface disease.
FinSMEs
07/11/2017